Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a selective and orally active hSGLT2 inhibitor with an IC50 of 0.877 nM. Ertugliflozin L-pyroglutamic acid can be used for studies about the treatment of type 2 diabetes mellitus.
説明 | Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a selective and orally active hSGLT2 inhibitor with an IC50 of 0.877 nM. Ertugliflozin L-pyroglutamic acid can be used for studies about the treatment of type 2 diabetes mellitus. |
ターゲット&IC50 | SGLT2 (human):0.877 nM |
別名 | PF-04971729 L-pyroglutamic acid |
分子量 | 566 |
分子式 | C27H32ClNO10 |
CAS No. | 1210344-83-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (220.85 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ertugliflozin L-pyroglutamic acid 1210344-83-4 GPCR/G Protein Others SGLT inhibit Sodium-dependent glucose cotransporters Inhibitor Ertugliflozin L pyroglutamic acid PF-04971729 L-pyroglutamic acid Ertugliflozin Lpyroglutamic acid inhibitor